Skinbiotherapeutics’ (SBTX) Corporate Rating Reaffirmed at Northland Securities

Northland Securities reaffirmed their corporate rating on shares of Skinbiotherapeutics (LON:SBTX) in a research note issued to investors on Thursday.

LON:SBTX traded up GBX 0.75 ($0.01) during mid-day trading on Thursday, hitting GBX 19.25 ($0.25). 43,571 shares of the company’s stock were exchanged, compared to its average volume of 261,826. Skinbiotherapeutics has a fifty-two week low of GBX 7.07 ($0.09) and a fifty-two week high of GBX 17.75 ($0.23).

Skinbiotherapeutics Company Profile



SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd.

See Also: Closed-End Mutual Funds

Receive News & Ratings for Skinbiotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skinbiotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply